Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase 1 2Phase 1/2 1

Status

Completed 3Recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 4

Conditions

Neuroblastoma 3Ganglioneuroblastoma 1

Interventions

Specimen Handling 274Magnetic Resonance Spectroscopy 226pembrolizumab 225Carboplatin 178Biopsy 165Cisplatin 162Nivolumab 157Cyclophosphamide 146Paclitaxel 124Radiotherapy 123Gemcitabine 114Bevacizumab 92durvalumab 91Dexamethasone 87Rituximab 80Oxaliplatin 80venetoclax 73atezolizumab 70Doxorubicin 70Fluorouracil 69Docetaxel 69Capecitabine 68Etoposide 66Radiosurgery 65Ipilimumab 63Radiation 60Prednisone 60Cytarabine 60Lenalidomide 59fludarabine 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × dinutuximab × 90 days × Clear all
NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT02308527 2026-05-12

BEACON

University of Birmingham

Phase 2 Completed
225 enrolled
CNS

Neuroblastoma

NCT01857934 2026-04-16

Therapy for Children With Advanced Stage Neuroblastoma

St. Jude Children's Research Hospital

Phase 2 Completed
153 enrolled 12 charts
CNS

Neuroblastoma

NCT06450041 2026-03-23

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

New Approaches to Neuroblastoma Therapy Consortium

Phase 2 Recruiting
62 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡